Navigation Links
Liquid biomaterials take stem cell therapy to new level
Date:3/17/2011

At present, cartilage implants created using stem cells can only be constructed as a solid shape, acting as an interim measure before the almost inevitable need for total joint replacement.

Now researchers at the University of Bristol are investigating the possibilities of a biologically-engineered synthetic liquid polymer that would eliminate the need for further surgery by offering a one stop, permanent solution.

Dr Wael Kafienah, from Bristol's School of Medical Sciences, believes this research could represent the next breakthrough in stem cell therapy. He and his team are collaborating with researchers in Canada and Qatar to explore how such a biomaterial could be created. Dr Kafienah, the lead Principal Investigator for Bristol, has been funded by the Qatar National Research Fund (QNRP), with approximately $1 million over a period of three years to conduct the initial research. The QNRP has an international annual cycle of highly competitive, peer-reviewed, collaborative funding.

If the research proves successful, clinical trials could be carried out within five years.

Initial research shows that an injectable gel would have the capacity to form three-dimensional scaffolds that could be moulded to assume the solid form of even an irregularly shaped defected area, resulting in the formation of new tissue that would fully fill the defect at the point of delivery and encourage the growth of healthy cells.

A gel-based biomaterial could also be used for immunotherapy, where stem cells injected into the body would stimulate the immune system to destroy the tumour by providing a source of gene therapies or therapeutic vaccines. Injecting these stem cells in the form of a gel would allow clinicians to target the tumour through a prolonged, controlled release of the therapeutic proteins required, with obvious benefits to the patient as there would be fewer courses of treatment.

Dr Kafienah said: "The versatility of injectable polymers and stem cells opens up endless opportunities for cell-based therapies. For instance, the polymer-cell constructs can be used to create cartilage implants that can grow at the defect site without the need for the expensive process of growing the tissue in the lab before hand. The technology can also aid bone fracture repair where the presence of stem cells is shown to enhance bone repair capacity but require a flexible vehicle to sustain their delivery. There is a rapidly expanding area of regenerative medicine that is hugely dependent on injectable biomaterials. The novel biomaterials we are working on would be ideal for this, given what we anticipate to be their superior mechanical properties and cell guiding chemistry."

The research builds on the advances already made by Bristol's team of stem cell and tissue engineering experts in creating cartilage from adult human bone marrow stem cells, coupled with the work of researchers at Memorial University of Newfoundland in Canada and Qatar University in creating novel injectable biomaterials for cartilage tissue engineering.


'/>"/>

Contact: Aliya Mughal
aliya.mughal@bristol.ac.uk
44-117-331-7033
University of Bristol
Source:Eurekalert

Related medicine news :

1. A new high-resolution method for imaging below the skin using a liquid lens
2. Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid
3. Announcing NutriVite, Liquid Multivitamin Shots - Welcome to the Future of Vitamins
4. GMP Labs Expands Liquid Nutraceutical Capabilities
5. New Liquid Functional Nutrition Products: EYL Beverages Announces Debut of DeCOMPRESS™ and Debug™ Beverages at Natural Products EXPO West
6. Liquid Love: Last Minute Valentines Day Gift For Your Heart
7. New therapy found for rare lung disorder
8. Sirolimus therapy alleviates symptoms of lung disease LAM
9. Research study explores gene therapy treatment to reduce symptoms of Parkinsons disease
10. University Hospitals Case Medical Center testing innovative heat therapy for premature ejaculation
11. Ohio State study: Targeted ovarian cancer therapy not cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel of ... of proceeds to two local organizations: North Chicago Animal Control and Friends and Our ... a team of authorized and trained volunteers who support rescued animals held in the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... The ... the holidays and winter seasons. One major study analyzing heart attacks among 138,602 ... to August of a given year. We would all agree of course–no time of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology: